Nutriband Inc. Authorizes $1M Share Buyback Program
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has authorized a $1 million share buyback program for its common stock. As of September 16, 2024, the company had 11,106,185 outstanding common shares. Nutriband is primarily focused on developing transdermal pharmaceutical products, with its lead product being an abuse deterrent fentanyl patch incorporating the AVERSA™ abuse deterrence technology. The company maintains its target of submitting an NDA to the FDA in Q1/Q2 2025 for AVERSA Fentanyl. AVERSA™ technology can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ha autorizzato un programma di riacquisto di azioni da 1 milione di dollari per le sue azioni ordinarie. Al 16 settembre 2024, l'azienda aveva 11.106.185 azioni ordinarie in circolazione. Nutriband è principalmente focalizzata sullo sviluppo di prodotti farmaceutici transdermici, con il suo prodotto di punta che è un cerotto al fentanyl con deterrenza all'abuso che integra la tecnologia AVERSA™ di deterrenza all'abuso. L'azienda mantiene l'obiettivo di presentare una NDA alla FDA nel Q1/Q2 2025 per AVERSA Fentanyl. La tecnologia AVERSA™ può essere integrata in qualsiasi cerotto transdermico per prevenire abusi, usi impropri, deviazione e esposizione accidentale a farmaci con potenziale di abuso.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ha autorizado un programa de recompra de acciones de 1 millón de dólares para sus acciones ordinarias. A partir del 16 de septiembre de 2024, la empresa contaba con 11,106,185 acciones ordinarias en circulación. Nutriband se centra principalmente en el desarrollo de productos farmacéuticos transdérmicos, siendo su principal producto un parche de fentanilo con acción disuasoria contra el abuso que incorpora la tecnología AVERSA™ para la disuasión del abuso. La empresa mantiene su objetivo de presentar una NDA a la FDA en el Q1/Q2 de 2025 para AVERSA Fentanilo. La tecnología AVERSA™ se puede integrar en cualquier parche transdérmico para prevenir el abuso, el uso indebido, la desviación y la exposición accidental a medicamentos con potencial de abuso.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW)는 100만 달러 규모의 자사주 매입 프로그램을 승인했습니다. 2024년 9월 16일 기준으로 이 회사는 11,106,185주의 보통주가 발행되었습니다. Nutriband는 주로 경피 약제 제품 개발에 집중하고 있으며, 주요 제품은 AVERSA™ 남용 방지 기술을 포함한 남용 방지 펜타닐 패치입니다. 이 회사는 2025년 1분기/2분기에 FDA에 AVERSA 펜타닐에 대한 NDA를 제출할 계획을 유지하고 있습니다. AVERSA™ 기술은 남용 방지, 잘못된 사용, 전용 및 약물의 우발적 노출을 방지하기 위해 모든 경피 패치에 통합될 수 있습니다.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) a autorisé un programme de rachat d'actions de 1 million de dollars pour ses actions ordinaires. Au 16 septembre 2024, la société comptait 11 106 185 actions ordinaires en circulation. Nutriband est principalement axée sur le développement de produits pharmaceutiques transdermiques, son produit phare étant un patch de fentanyle dissuadant l'abus intégrant la technologie AVERSA™ de dissuasion à l'abus. L'entreprise maintient son objectif de soumettre une NDA à la FDA au 1er/2ème trimestre 2025 pour l'AVERSA Fentanyl. La technologie AVERSA™ peut être intégrée dans tout patch transdermique pour prévenir l'abus, l'usage inapproprié, la dérivation et l'exposition accidentelle à des médicaments à potentiel d'abus.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) hat ein Aktienrückkaufprogramm im Wert von 1 Million Dollar genehmigt für ihre Stammaktien. Zum 16. September 2024 hatte das Unternehmen 11.106.185 ausgegebene Stammaktien. Nutriband konzentriert sich hauptsächlich auf die Entwicklung transdermaler pharmazeutischer Produkte, wobei das Hauptprodukt ein missbrauchsverhindernder Fentanyl-Patch ist, der die AVERSA™-Technologie zur Missbrauchsverhinderung integriert. Das Unternehmen hält an seinem Ziel fest, im Q1/Q2 2025 einen NDA bei der FDA für AVERSA Fentanyl einzureichen. Die AVERSA™-Technologie kann in jeden transdermalen Patch integriert werden, um Missbrauch, Fehlgebrauch, Abzweigung und versehentliche Exposition gegenüber Drogen mit Missbrauchspotenzial zu verhindern.
- Authorization of $1 million share buyback program, potentially increasing shareholder value
- Progress on AVERSA Fentanyl development, with NDA submission target maintained for Q1/Q2 2025
- Potential market opportunity for abuse deterrent transdermal patch technology
- None.
Insights
Nutriband's
The buyback could provide some support to the share price, especially if executed during market dips. However, investors should note that
The ongoing development of AVERSA Fentanyl is important for Nutriband's future. The abuse-deterrent fentanyl patch addresses a critical need in pain management, potentially reducing the risks associated with opioid misuse. The targeted NDA submission in Q1/Q2 2025 provides a clear timeline for investors to monitor progress.
However, it's important to note that the FDA approval process can be lengthy and unpredictable, especially for novel drug delivery systems. Investors should be prepared for possible delays or additional data requests from the FDA. The success of AVERSA technology could have broader implications, as it's designed to be incorporated into various transdermal patches, potentially creating a platform technology with multiple applications in the pharmaceutical industry.
ORLANDO, FL / ACCESSWIRE / September 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced a share repurchase program to buy back up to
Progress continues on the development of AVERSA Fentanyl, with the Company maintaining its target of submitting an NDA to the FDA in Q1/Q2 2025
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes,'' "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2024 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
For more information, contact:
RedChip Companies, Inc.
Email: NTRB@Redchip.com
Phone: 1-407-644-4256
Address:
431 E Horatio Ave, Suite #100
Maitland, FL 32751
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband, Inc.
View the original press release on accesswire.com
FAQ
What is the value of Nutriband Inc.'s (NTRB) authorized share buyback program?
How many outstanding common shares does Nutriband Inc. (NTRB) have as of September 16, 2024?
What is Nutriband Inc.'s (NTRB) lead product under development?